Logo image of SBFM

SUNSHINE BIOPHARMA INC (SBFM) Stock Fundamental Analysis

NASDAQ:SBFM - Nasdaq - US8677817004 - Common Stock - Currency: USD

1.4  -0.02 (-1.41%)

After market: 1.43 +0.03 (+2.14%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to SBFM. SBFM was compared to 561 industry peers in the Biotechnology industry. The financial health of SBFM is average, but there are quite some concerns on its profitability. SBFM is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SBFM had negative earnings in the past year.
SBFM had a negative operating cash flow in the past year.
In the past 5 years SBFM always reported negative net income.
In the past 5 years SBFM always reported negative operating cash flow.
SBFM Yearly Net Income VS EBIT VS OCF VS FCFSBFM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

SBFM's Return On Assets of -16.80% is fine compared to the rest of the industry. SBFM outperforms 79.68% of its industry peers.
SBFM's Return On Equity of -21.85% is amongst the best of the industry. SBFM outperforms 84.31% of its industry peers.
Industry RankSector Rank
ROA -16.8%
ROE -21.85%
ROIC N/A
ROA(3y)-41.58%
ROA(5y)-191.13%
ROE(3y)-55.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SBFM Yearly ROA, ROE, ROICSBFM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K 4K -4K 6K

1.3 Margins

SBFM's Gross Margin of 30.60% is fine compared to the rest of the industry. SBFM outperforms 73.44% of its industry peers.
SBFM's Gross Margin has declined in the last couple of years.
SBFM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.34%
GM growth 5Y-8.47%
SBFM Yearly Profit, Operating, Gross MarginsSBFM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

SBFM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SBFM has more shares outstanding
Compared to 5 years ago, SBFM has more shares outstanding
SBFM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SBFM Yearly Shares OutstandingSBFM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SBFM Yearly Total Debt VS Total AssetsSBFM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

SBFM has an Altman-Z score of -1.43. This is a bad value and indicates that SBFM is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.43, SBFM is in line with its industry, outperforming 58.29% of the companies in the same industry.
SBFM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.43
ROIC/WACCN/A
WACC10.06%
SBFM Yearly LT Debt VS Equity VS FCFSBFM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 4.11 indicates that SBFM has no problem at all paying its short term obligations.
SBFM's Current ratio of 4.11 is in line compared to the rest of the industry. SBFM outperforms 48.48% of its industry peers.
A Quick Ratio of 2.33 indicates that SBFM has no problem at all paying its short term obligations.
SBFM's Quick ratio of 2.33 is on the low side compared to the rest of the industry. SBFM is outperformed by 70.05% of its industry peers.
Industry RankSector Rank
Current Ratio 4.11
Quick Ratio 2.33
SBFM Yearly Current Assets VS Current LiabilitesSBFM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 27.21% over the past year.
The Revenue has grown by 44.75% in the past year. This is a very strong growth!
Measured over the past years, SBFM shows a very strong growth in Revenue. The Revenue has been growing by 340.61% on average per year.
EPS 1Y (TTM)27.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99%
Revenue 1Y (TTM)44.75%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%24.93%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y101.45%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year164.69%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SBFM Yearly Revenue VS EstimatesSBFM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
SBFM Yearly EPS VS EstimatesSBFM Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 0 -100 -200 -300

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SBFM. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 1.85, the valuation of SBFM can be described as very cheap.
99.11% of the companies in the same industry are more expensive than SBFM, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of SBFM to the average of the S&P500 Index (21.85), we can say SBFM is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 1.85
SBFM Price Earnings VS Forward Price EarningsSBFM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SBFM Per share dataSBFM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40

4.3 Compensation for Growth

SBFM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SBFM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SUNSHINE BIOPHARMA INC

NASDAQ:SBFM (5/22/2025, 8:00:02 PM)

After market: 1.43 +0.03 (+2.14%)

1.4

-0.02 (-1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-19 2025-05-19
Earnings (Next)08-14 2025-08-14
Inst Owners0.56%
Inst Owner Change759.81%
Ins Owners0.1%
Ins Owner Change0%
Market Cap5.10M
Analysts82.86
Price Target306 (21757.14%)
Short Float %11.33%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-550.75%
Min EPS beat(2)-991.27%
Max EPS beat(2)-110.24%
EPS beat(4)0
Avg EPS beat(4)-305.43%
Min EPS beat(4)-991.27%
Max EPS beat(4)-31.69%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-27.33%
Min Revenue beat(2)-29.92%
Max Revenue beat(2)-24.75%
Revenue beat(4)2
Avg Revenue beat(4)-11.93%
Min Revenue beat(4)-29.92%
Max Revenue beat(4)5.62%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.85
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B 0.22
P/tB 0.25
EV/EBITDA N/A
EPS(TTM)-51.88
EYN/A
EPS(NY)0.75
Fwd EY53.91%
FCF(TTM)-3.99
FCFYN/A
OCF(TTM)-3.44
OCFYN/A
SpS9.58
BVpS6.46
TBVpS5.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.8%
ROE -21.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.6%
FCFM N/A
ROA(3y)-41.58%
ROA(5y)-191.13%
ROE(3y)-55.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.34%
GM growth 5Y-8.47%
F-Score2
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 885.59%
Cap/Sales 5.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.11
Quick Ratio 2.33
Altman-Z -1.43
F-Score2
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)874.71%
Cap/Depr(5y)526.53%
Cap/Sales(3y)5.32%
Cap/Sales(5y)3.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99%
EPS Next Y101.45%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)44.75%
Revenue growth 3Y434.8%
Revenue growth 5Y340.61%
Sales Q2Q%24.93%
Revenue Next Year164.69%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-51.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.8%
OCF growth 3YN/A
OCF growth 5YN/A